Objective: To compare long-term outcome of R0 (negative margins) and R1 (positive margins) liver resections for colorectal liver metastases (CLM) treated by an aggressive approach combining chemotherapy and repeat surgery. Summary Background Data: Complete macroscopic resection with negative margins is the gold standard recommendation in the surgical treatment of CLM. However, due to vascular proximity or multinodularity, complete macroscopic resection can sometimes only be performed through R1 resection. Increasingly efficient chemotherapy may have changed long-term outcome after R1 resection. Methods: All resected CLM patients (R0 or R1) at our institution between 1990 and 2006 were prospectively evaluated. Exclusion criteria were: macroscopic incomplete (R2) resection, use of local treatment modalities, and presence of extrahepatic disease. We aimed to resect all identified metastases with negative margins. However, when safe margins could not be obtained, resection was still performed provided complete macroscopic tumor removal. Overall survival (OS) and disease-free survival were compared between groups, and prognostic factors were identified. Results: Of 840 patients, 436 (52%) were eligible for the study, 234 (28%) of whom underwent R0 resection, and 202 (24%) underwent R1 resection. Number and size of CLM were higher, and distribution was more often bilateral in the R1 group. After a mean follow-up of 40 months, 5-year OS was 61% and 57% for R0 and R1 patients (P ϭ 0.27). Five-year disease-free survival was 29% in the R0 group versus 20% in the R1 group (P ϭ 0.12). In the R1 group, intrahepatic (but not surgical margin) recurrences were more often observed (28% vs. 17%; P ϭ 0.004). Preoperative carcinoembryonic antigen level Ն10 ng/mL and major hepatectomy, but not R1 resection, were independent predictors of poor OS. Size Ն30 mm, bilateral distribution, and intraoperative blood transfusions independently predicted positive surgical margins. Conclusions: Despite a higher recurrence rate, the contraindication of R1 resection should be revisited in the current era of effective chemotherapy because survival is similar to that of R0 resection. (Ann Surg 2008;248: 626 -637) L iver resection is still the only chance of cure for patients with colorectal metastases, resulting in 5-year survival rates up to 67% for highly selected patients.
L
iver resection is still the only chance of cure for patients with colorectal metastases, resulting in 5-year survival rates up to 67% for highly selected patients. 1 Unfortunately, at the time of diagnosis, only one-fifth of patients with colorectal liver metastases (CLM) presents with resectable lesions. 2 Nowadays, an important amount of patients initially considered as having unresectable CLM can be converted to resectability by the aid of modern chemotherapy regimens consisting of 5-fluorouracil, leucovorin, oxaliplatin, and/or irinotecan. [3] [4] [5] [6] In addition, chemotherapy efficacy can be further increased by the use of monoclonal antibodies like cetuximab and bevacizumab. [7] [8] [9] Besides this, surgical improvements like portal vein embolization, which allows hypertrophy of a small remnant liver volume, and vascular resection and reconstruction techniques enable hepatic resection in an additional number of patients. 10, 11 However, due to the increased number of patients with multinodular disease and/or CLM close to important vascular structures, macroscopic complete resection of all CLM can sometimes only be performed with positive surgical margins.
Within the literature, the inability to achieve clear resection margins is generally considered as contraindication to surgery because it has been associated with significantly reduced survival rates, [12] [13] [14] [15] [16] [17] [18] [19] [20] and an increased risk of surgical margin recurrence. 16, 21 Several cutoff points for the optimal negative resection margin width have been proposed, varying between 2 and 10 mm; [22] [23] [24] [25] [26] [27] [28] however, complete macroscopic removal of all lesions with negative resection margins, irrespective of the width, is currently the gold standard recommendation in the surgical treatment of CLM.
At our institute, the inability to obtain a free surgical margin during liver resection for CLM has never been considered a contraindication to surgery, provided complete macroscopic removal of all metastatic lesions. As increasingly effective chemotherapy regimens might have changed the spectrum of this particular situation, we compared longterm outcome in patients with microscopically positive and negative resection margins who were all treated by an aggressive approach consisting of chemotherapy and repeat surgery to assess the validity of this policy.
METHODS

Study Population
All consecutive patients treated by hepatic resection for CLM at our hospital between January 1990 and January 2006, and who fulfilled the following criteria were eligible for the study: (1) macroscopic complete resection; (2) clear description of surgical margin status by the pathologist for each metastasis; (3) no evidence of concomitant extrahepatic disease; (4) no simultaneous use of local treatment modalities (ie, radiofrequency ablation and/or cryosurgery). Patients were selected from our prospectively maintained institutional database, and each medical chart was reviewed.
Preoperative Evaluation
All patients were preoperatively evaluated by thoracoabdominal imaging (ultrasonography, computed tomography (CT)), routine blood tests, serum tumor marker levels (carcinoembryonic antigen (CEA) and/or CA19.9), and colonoscopy. Preoperative chemotherapy was administered when liver metastases were initially unresectable (ie, inability to completely remove all CLM with a sufficient remnant liver volume), or in a neoadjuvant setting in case of synchronous (diagnosed before, during, or within 3 months after colorectal resection) or in case of marginally resectable (Ն5 bilateral nodules) CLM. Chemotherapy response was monitored every 2 months by CT imaging, according to the World Health Organization guidelines 29 or, more recently, by using the Response Evaluation Criteria in Solid Tumors (RECIST). 30 If the estimated future remnant liver volume was still insufficient after chemotherapy, portal vein embolization was performed to induce compensatory hypertrophy of the remaining liver.
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Hepatic Resection
During laparotomy, thorough abdominal exploration was performed to rule out extrahepatic disease sites. Palpation of the liver and intraoperative ultrasound were carried out to confirm the number and size of the lesions, to define their relation with intrahepatic vascular structures, and to search for occult CLM. Parenchymal transection was performed using the ultrasonic dissector (Cavitron Ultrasonic Surgical Aspirator, Valleylab, Boulder, CO) and a fenestrated bipolar forceps. The goal of surgery was to resect all identified tumor deposits with a tumor-free margin. However, when a tumor-free resection margin could not be obtained, owing to vascular proximity or multinodularity, resection was still performed provided that all metastatic lesions were macroscopically completely removed. To prevent local recurrences in these cases, application of argon beam or bipolar coagulation was routinely performed on the cut section. Postoperatively, all resection specimens were examined by conventional histopathological examination. According to the guidelines of the International Union Against Cancer, R0 and R1 resections were defined by the absence (tumor-free margin Ն1 mm for all detected lesions) or presence (tumorfree margin 0 mm) of microscopic tumor invasion of the resection margins, respectively. 31 In case of microscopic tumor invasion, the additional opinion of the operating surgeon with regard to the complete macroscopic resection of all lesions, differentiated R1 from R2 resections.
Postoperative Follow-Up
Regular postoperative follow-up started at 1 month posthepatectomy, and then every 4 months, consisting of routine blood tests, serum tumor marker evaluation (CEA and/or CA19.9), and hepatic ultrasound. Thoracoabdominal CT imaging was performed every 8 months. After hepatectomy, patients were treated by systemic chemotherapy to decrease the recurrence risk. If an intrahepatic and/or extrahepatic recurrence occurred, repeat surgery was performed if potentially curative.
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Statistical Analysis
To assess the impact of R1 resections on long-term outcome, patients were divided according to their surgical margin status into a R0 group and a R1 group. 2 test was used to compare categorical data, and continuous data were compared using the independentsamples t test. Survival time was calculated from the date of hepatic resection until death or last follow-up. Progression-free survival (PFS) was defined as the time-interval between hepatectomy and first postoperative recurrence or death, whereas disease-free survival (DFS) was defined as the time-interval between the hepatectomy and either the first recurrence that could not be curatively treated (resection or ablation) or death. Survival curves were generated by the Kaplan-Meier method, and were compared by the log-rank test. To identify predictors of survival, univariate and multivariate analyses were performed, using the log-rank test and the Cox proportional hazard model, respectively. Furthermore, independent predictors of R1 resection were identified at multivariate analysis (logistic regression), including all factors most likely to influence surgical margin status with a P value Յ0.10 at univariate analysis. Statistical significance was defined as P Յ 0.05. All statistical analyses were performed by using SPSS version 13.0 (SPSS Inc., Chicago, IL). 
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RESULTS
Patients
Between January 1990 and January 2006, 840 patients underwent hepatic resection for CLM at our hospital, 436 (52%) of whom fulfilled the inclusion criteria (Fig. 1) . Fiftyseven patients (7%) were excluded because of a macroscopic incomplete (R2) liver resection, 128 patients (15%) because a clear description of the microscopic surgical margin status was not available for all metastases, 134 patients (16%) because of concomitant extrahepatic disease, and 85 patients (10%) because of a concomitant local treatment. Among the 436 eligible patients, microscopic tumor invasion at pathologic analysis was present in 202 patients (24%) (R1 group), whereas in 234 patients (28%) no viable tumor cells could be identified at the resection margin (R0 group).
Patients in the R1 group presented with more extensive liver disease, reflected by the higher number and larger size of metastases, which were more often bilaterally distributed and initially unresectable ( Table 1) .
Perioperative Characteristics
In both groups, the majority of patients were treated by preoperative chemotherapy; however, significantly more patients received preoperative chemotherapy in the R1 group (81% vs. 67%, P ϭ 0.001; Table 2 ). Although the number of preoperative chemotherapy lines was similar between both groups, a higher mean number of preoperative cycles was administered within the R1 group (9 Ϯ 6 cycles vs. 7 Ϯ 4 cycles, respectively; P ϭ 0.004). Preoperative portal vein embolization was more often needed to allow safe resection in patients in the R1 group (15% vs. 6%, P ϭ 0.002), and significantly more patients within the R1 group underwent a major hepatectomy (defined as Ն3 segments 33, 34 ) ( Table 2 ). Intraoperative ultrasound examination revealed in the R1 group significantly more often metastases located close (Ͻ1.0 cm) to a large blood vessel (51% vs. 35%, P Ͻ 0.001). Furthermore, a higher need of intraoperative vascular occlusion and red blood cell transfusion emerged in the R1 group.
In the R0 group, 3 patients (1%) died within 60 days postoperatively, compared with 1 postoperative death (0.5%) in the R1 group (P ϭ 0.38). Causes of death were ischemic cardiovascular accident (N ϭ 1), aspiration pneumonia (N ϭ 1), cardiac arrest of unknown cause (N ϭ 1), and ischemic colitis (N ϭ 1). The postoperative complication rate was higher in the R1 group (42% vs. 32%, P ϭ 0.03), more often related to hepatic causes (Table 2 ). However, severity of the complications according to the Clavien classification was equally distributed between both groups. 35 Postoperatively, most patients received adjuvant chemotherapy, which was again more frequently administered in the R1 group (88% vs. 78%, P ϭ 0.002).
Long-Term Outcome
Mean follow-up for the entire study population was 40 months. At last follow-up, 75 patients (32%) in the R0 group had died, and 159 (68%) were alive, of whom 93 (40%) were disease-free (Table 3) . Within the R1 group, 63 patients (31%) had died at last follow-up, and 139 (69%) were alive, 63 (31%) of whom were without evidence of disease recurrence.
Disease recurrence tended to occur more often in patients who had undergone R1 resection. When subdivided according to recurrence location, significantly more intrahepatic recurrences were observed after R1 resections. However, the rate of recurrences located at the surgical margin was similar between both groups (Table 3) . Thirty-nine percent of the total study population developed a recurrence within the first year after hepatic resection, a further 19% had a first recurrence in the second year, and a further 11% had a first recurrence in the next 2 to 5 years. A total of 182 patients (42%) developed an intrahepatic recurrence, 99 (54%) of whom underwent repeat hepatectomy. An extrahepatic located disease recurrence was diagnosed in 234 patients (54%), 85 (36%) of whom were treated by repeat surgery.
Five-year and 10-year overall survival (OS) rates were 61% and 43% in the R0 group, versus 57% and 37% in the R1 
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group, respectively (P ϭ 0.27) (Fig. 2 ). Median survival rates were 77 and 84 months for the R0 and R1 group, respectively. Five-year and 10-year PFS rates were 23% and 19% in the R0 group, compared with 14% and 12% within the R1 group, respectively (median: 15 vs. 14 months; P ϭ 0.11) (Fig. 3) . DFS rates after 5 and 10 years were also slightly lower for the R1 group (20% and 11% vs. 29% and 17%, respectively; median: 21 vs. 23 months); however, again, statistical significance was not reached (P ϭ 0.12) (Fig. 4) . Within the R0 group, 15 actual 10-year survivors (6%) were present, of whom all but one were disease-free at last follow-up. Likewise, the R1 group contained 7 actual 10-year survivors (3%), which were all without evidence of disease recurrence at last follow-up. The difference between PFS and DFS rates in the R0 group and R1 group, obtained by repeat resection of hepatic and/or extrahepatic recurrences is demonstrated in Figures 5 and 6 , respectively.
Predictive Factors of Survival
Univariate analysis identified 7 factors which significantly influenced OS: number of liver metastases at diagnosis, initial resectability, CEA level at diagnosis, clinical response at CT-scan after preoperative chemotherapy, preoperative CEA level, extent of liver resection, and largest metastasis size at histopathologic examination (Table 4) . At multivariate analysis, preoperative CEA level 
Ն10 ng/mL, and major hepatectomy, but not R1 resection, were independent predictors of poor outcome (Table 4) .
Predictive Factors of R1 Resection
Multivariate analysis identified 3 factors that were independently associated with microscopic tumor invasion of the surgical margin: size of the largest liver metastasis Ն30 mm, bilateral distribution of liver metastases, and intraoperative red blood cell transfusion (Table 5) .
DISCUSSION
Within the current study, we investigated the influence of surgical margin status (ie, microscopically involved vs. clear margins) on long-term outcome in patients with CLM treated by an aggressive approach consisting of chemotherapy and repeat surgery. Five-year OS rate was 57% in the R1 group, not significantly different from 61% after R0 resection. Five-year PFS and DFS rates were slightly better for R0 resections, but did not significantly differ between both groups ͓23% and 29% after R0 resection vs. 14% and 20% after R1 resection, respectively; P ϭ 0.11 (PFS) and P ϭ 0.12 (DFS)͔. Although more intrahepatic recurrences were observed in the R1 group, the rate of surgical margin recurrences was comparable between both groups. Maximum diameter of the largest liver metastasis Ն30 mm, bilateral distribution of liver metastases, and intraoperative red blood cell transfusion independently predicted microscopic involvement of the surgical margins. Overall, a preoperative CEA level Ն10 ng/mL and a major hepatectomy were identified as independent predictors of poor survival. Microscopic involvement of surgical resection margins emerged in many publications as a significant poor prognostic factor. [12] [13] [14] [15] [16] [17] [18] [19] [20] Therefore, the inability to obtain clear surgical margins has been considered a contraindication to liver surgery for CLM. However, the optimal negative surgical margin width correlated with best long-term outcome is still unclear. Within the literature, several cutoff points have been proposed, varying between 2 and 10 mm. [22] [23] [24] [25] [26] [27] [28] Important data concerning the optimal surgical margin width has been provided by Kokudo et al. 25 By using a sensitive genetic analysis for detecting K-ras and p53 mutations, micrometastases in the liver parenchyma surrounding CLM were found in only 2% of patients, all within 4 mm of the tumor border. 25 In another recent publication, the pattern of chemotherapy response of CLM was evaluated, to define the optimal surgical approach after chemotherapy for liver metastases. 26 The response of CLM after chemotherapy was found to consist of tumor shrinkage in a concentric fashion and of random tumor cell death throughout the metastasis. 26 Notably, nests of viable tumor cells were never found further than 4 mm from the peripheral edge of the main tumor. 26 However, based on the currently available data, complete macroscopic resection with negative surgical margins is the gold standard recommendation in the surgical treatment of CLM. We have questioned for long the inability to achieve microscopically clear surgical margins as an absolute contraindication for surgery in patients with CLM for different reasons.
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First, the ultrasonic dissector, which is routinely used in hepatic resections, aspires a small rim of hepatic tissue, thereby possibly decreasing the resection margin for 1 to 2 mm. This potential overestimation of the proportion of R1 resections has also been recognized by Pawlik et al. 21 Ultrasonic dissectors are nowadays used by most centers, and therefore our findings represent current daily practice.
Second, the remnant cut section of the liver at the contact of the removed tumor is treated as much as possible with argon beam or bipolar coagulation, which "sterilizes" an extra 1 to 2 mm of hepatic tissue. Although none of the publications in which microscopic surgical margin involvement emerged as a poor prognostic factor described the use of these additional techniques, surgical teams have this possibility. [12] [13] [14] [15] [16] [17] [18] [19] [20] A third reason is that more effective chemotherapy regimens could reduce the proportion of metastases that develop satellite nodules, thus minimizing residual micrometastatic disease. Within our population, 74% of patients received preoperative chemotherapy, and in 83% of patients surgery was followed by adjuvant chemotherapy. This contrasts with the existing literature, reporting only one-third of patients receiving preoperative chemotherapy. 19, 22 Finally, even in case of local recurrence, repeat hepatectomy may offer a chance of long-term survival, 32 whereas chemotherapy alone, if we contraindicate surgery, is merely palliative. The value of repeat (extra) hepatic surgery in our population is clearly demonstrated by the difference between PFS and DFS ( Figs. 5 and 6) . Accordingly, the results of our study demonstrate that not considering the inability to obtain microscopically clear surgical margins as an absolute contraindication for surgery has been a reasonable treatment strategy. Importantly, by excluding patients who underwent R2 resection, or with concomitant local ablative techniques, and those presenting with concomitant extrahepatic disease, the real impact of surgical margin status on survival could be identified.
5
In the recent multicenter study reported by Pawlik et al, 21 a positive surgical margin was significantly associated with surgical margin recurrence. Similarly, Hamady et al observed a higher recurrence rate located at the surgical margin in patients with positive resection margins. 16 Likewise, Choti et al identified microscopically positive resection margins as an independent factor predicting worse DFS; however, recurrences were not stratified according to their location. 12 In addition, Kokudo et al reported an increase in resection margin recurrences in patients with surgical margins narrower than 2 mm. 25 In the present study, although more intrahepatic recurrences were observed in patients with positive resection margins, the rate of surgical margin recurrences and intrahepatic recurrences away from the surgical margin were equally balanced between the R0 group and the R1 group. This is in agreement with a recent publication by Bodingbauer et al, in which it was demonstrated that surgical margin status was not associated with an increased hepatic recurrence risk, either at the surgical margin or elsewhere. 36 Figueras et al also recently reported that subcentimeter nonpositive surgical margins did not influence hepatic recurrence rates after hepatectomy for CLM. 37 That positive surgical margins expose to a higher recurrence risk is obvious, but this should not be the only criterion considered. By stating R1 resection as a contraindication to surgery, what should be the alternative? Even with the increasingly efficient chemotherapy regimens, median survivals reach currently 20 to 24 months. 38, 39 By combining liver resection (even R1), we quadruple the survival expectancy, since median survival was in our study 88 months after R1 resection. Therefore, no doubt is allowed, provided that the resection is complete.
Our multivariate analysis demonstrated that an increased preoperative CEA level and the performance of a major hepatectomy independently predicted poor outcome. In several other publications, an increased preoperative CEA level also emerged as a predictor of worse long-term outcome.
12,14,27 By contrast, major hepatectomy by itself is not a widely reported poor prognostic factor; however, it reflects the number, size, and distribution of CLM, which are well known risk factors for adverse long-term outcome. 14, 40, 41 Not surprisingly, size and distribution of CLM were identified as risk factors for the inability to obtain microscopically tumorfree surgical margins, which reflect tumor load and thereby complexity of achieving a radical clearance. Are et al and Pawlik et al, both, recently reported similar predictors of surgical margin involvement. 21, 22 Interestingly, in the present study we identified the need for red blood cell transfusion as a significant risk factor for R1 resection. A possible explanation relies on the fact that the need for an intraoperative red blood cell transfusion reflects a more complex operation with higher blood loss, in which it is technically more difficult to obtain free surgical margins.
In conclusion, despite a higher intrahepatic recurrence rate, OS, PFS and DFS rates were almost similar for patients with R0 and R1 resections for CLM, treated by an aggressive strategy consisting of chemotherapy and surgery. As chemotherapy regimens are nowadays increasingly effective, the inability to obtain microscopically free surgical margins as a contraindication to hepatic resection for CLM, provided macroscopic complete removal, should be revisited. As a result, long-term outcome after R1 resections should no longer be considered as poor as that observed after R2 resections, but closer to that observed after R0 resections. The absolute contraindication to hepatic resection for CLM should therefore not include R1 resection anymore.
Discussions
DR. MICHAEL A. CHOTI (BALTIMORE, MARYLAND): Surgical management of hepatic colorectal metastases has evolved significantly in recent years. Increasingly aggressive operations and the use of more active systemic agents, and improvements in imaging and patient selection have all contributed to improved outcomes and increased optimism for patients with advanced colorectal cancer. Even resectability has been redefined, rather than basing it on prognostic factors such as metastases size and number, it is based more on the capability to safely perform complete or R0 resection. In this study, you challenge even the necessity to achieve negative margins.
As you mentioned, several factors may be contributing to this observation. One factor may be the method for transecting the liver parenchyma and achieving hemostasis of the surface, resulting in an extra margin. Your group uses the ultrasonic dissector and the argon beam coagulation device. Newer techniques used by some include thermal devices for pretransection ablation. Can you comment on the role of these other coagulation devices? Is there a role for deeper thermal surface ablation in cases where the margin may be close?
The second point relates to defining exactly what an R1 resection margin is. I think a distinction needs to be made between an R1 resection in which the tumor truly extends microscopically to the specimen margin, compared with the situation in which a gross margin seems to have been achieved, but in the pathology report, a focal positive margin is noted. Often, the surface can fracture or crumble, resulting in ink at the tumor edge, perhaps leading to a false positive margin. Were you able to distinguish between these 2 variations and, if so, were there differences in outcome? Perhaps it is time to consider some kind of stratification of the R1 designation, something like R 0.5 versus R 1.5.
Finally, I would like to comment on the high margin recurrence rate seen in this study. Although you saw no significant difference between R0 and R1, the isolated margin recurrence rate was 12% and 15% respectively. This is higher than our experience and that of others, where we find a 10%-15% margin recurrence in R1 resection and approximately 5% for R0. Can you comment on how margin recurrences were determined in this study and why the local recurrence rate was so high?
DR. LESLIE H. BLUMGART (NEW YORK, NEW YORK): I have no quarrel with your conclusion, but can I ask you to define your R0 cases? Were they all a centimeter? Also, were the patients in the R0 group treated with the same chemotherapy, or was there a much greater preponderance of the new chemotherapy, which is much more effective, in your R1 group? DR. FREDERICK L. GREENE (CHARLOTTE, NORTH CAROLINA): As editor of the TNM Staging Manual, I have a practical question as we are preparing our seventh edition. The current definition of R0 is no histologic evidence of a tumor. Should we change our definition to mean that if there is tumor within 1 or 2 mm that should be an R1 and should not be R0? DR. BRYAN M. CLARY (DURHAM, NORTH CAROLINA): As I recall from one of your group's prior landmark publications, you demonstrated that patients with initially unresectable disease can be downsized to resectability. My recollection from that paper, though, is that those patients who required downsizing to resectability had a poorer outcome than those who were initially unresectable. I suspect a large number of your R1 patients were probably in that group who required downsizing. My question is, is there a difference in outcomes in people who require downsizing and have an R1 resection versus those who undergo an R1 without downsizing?
DR. RENE ADAM (VILLEJUIF, FRANCE): I would like to thank all the discussants for their interesting comments and questions. With regard to the question of Michael Choti, I would say that there is certainly a role of additional ablation in patients with R1 resection. I have mentioned the application of argon beam or bipolar coagulation to the raw surface of the transected liver. We have also used in the past, contact cryotherapy. Indeed, our routine policy was to cut the specimen just after the hepatectomy and when we saw that the resection margin was close to the tumor, we used whenever possible any "ablative" means to obtain a little increase (1-2 mm) in tumor-free hepatic tissue rim. However, we have not used radiofrequency ablation since our multiarray probes were not adapted to direct application surface.
The R1 definition is clearly an important point. We have used a combined definition meaning that the pathologist had to conclude that microscopically the minimal tumor-free margin was 0 mm, while the surgeon has to be sure that macroscopically all of the tumoral tissue has been removed. So, our definition of an R1 resection was based on the presence of these two conditions. With regards to the different subtypes of R1 resection I would agree with you that in some cases when we see intraoperatively a fractionated tumor, we may challenge the fact that we have removed all the tumor. This obviously may be different from a gross margin apparently negative macroscopically but turned positive on microscopy. However, to avoid subjective factors, we have considered all of the patients for whom the pathologist stated that the minimal tumor-free margin was 0 mm, and for whom the surgeon was convinced of having removed all macroscopic tumor deposits, irrespective of other factors of consideration.
It is true that among the total number of intrahepatic recurrences, 15% were located at the surgical margin following R0 liver resection, compared with 12% after an R1 liver resection. However, when the rate of surgical margin recurrences is calculated within the total group of patients that developed a recurrence (either intra-or extrahepatic), the percentages fall to 8% after an R0 resection and 9% after an R1 resection. The fact that these percentages do not widely differ could possibly rely on the presence in the R0 resection group of patients with no more than 1 or 2 mm safe margins, known to be at higher risk of recurrence than patients with larger margins. It further underlines that long-term outcome following R1 resections is close to that observed after R0 resections.
With regard to the question of Leslie Blumgart about the definition of R0 resections, I know that some discrepancy may exist regarding this definition, but clearly, R0 resection in our study concerned all patients in whom all tumoral deposits were removed by the surgeon with a tumor-free margin of at least 1 mm for each lesion. The fact that our definition of R0 resection includes a tumor-free margin for each lesion is, of course, an important point. In practice, when we were dealing with a patient that had 10 metastatic lesions, if only 1 lesion did not have a margin of security, this was for us sufficient not to consider this patient as R0 but as R1. For R0 resection, all lesions should have been removed with a tumor-free margin of at least 1 mm.
The type of chemotherapy used could, of course, have been critical for the results. In the current study, patients operated in 1990 were already treated with effective chemotherapy regimens. We had the chance to be one of the first hospitals in Europe using oxaliplatin since we used a chronomodulated regimen of 5-FU and oxaliplatin from 1988. This combination still continues to be part of the standard oncologic therapy. We did not use biotherapies at the time of the study, but clearly, chemotherapy treatment has been relatively homogeneous during the study period.
The question of Dr. Greene about the possible change of the TNM classification is of major importance. Maybe 1 or 2 mm-only safe margins could be better considered as an R1 resection if the recurrence rates are really different with such a modification of the present classification. However, the design and definitions used in our study do not allow us to answer the question of the potentially better discriminative value of 1 to 2 mm rather than 0 mm. The results, showing not so much difference between R0 (Ͼ 0 mm margin) and R1 (0 mm margin) resections, only argue for extending resection to patients of the latter group.
Coming to the last question of Dr. Clary about the rate of initial unresectability in the R1 patient group, clearly a majority of R1 patients were initially unresectable (56%), and this explains indeed why this population differs from that in the R0 patient group (only 31% initially unresectable). Concerning the point about a possible difference between patients that underwent an R1 resection while initially unresectable and R1 patients that were initially resectable, no differences in long-term outcome were observed in our study between both groups. However, in an even larger group of R1 patients, a survival difference might occur, as patients presenting with initially unresectable disease probably have less favorable tumor biology.
Many thanks again to all the discussants and to the ASA for giving me the opportunity to present this study.
